OSX.AX - Osteopore Limited
ASX - ASX Delayed price. Currency in AUD
As of 11:18AM AEST. Market open.
Stock chart is not supported by your current browser
| Previous close | 0.0840 |
| Open | 0.0860 |
| Bid | 0.0860 x 2236300 |
| Ask | 0.0880 x 971900 |
| Day's range | 0.0860 - 0.0880 |
| 52-week range | 0.0750 - 0.3050 |
| Volume | |
| Avg. volume | 89,439 |
| Market cap | 12.692M |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 28 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireKelyniam Global Releases Q1 Financials, Announces Licensing Agreement with Bioplate for Osteopore Products
Kelyniam Global (OTC: KLYG), a leading maker of custom cranial implants, today announced results for its quarter ended March 31, 2023.
PR NewswireOsteopore's Breakthrough Natural Tissue Regeneration Technology Leaps into Global Spotlight
Osteopore International (ASX:OSX) ("Osteopore", "OSX" or the "Company"), a Singapore- and Australia-based med-tech company focusing on facilitating natural tissue regeneration, is primed for the global limelight after quietly developing and commercialising its novel 3D-printed bioresorbable scaffold implants that have the potential to revolutionise the way surgeons help patients to naturally regrow bones and other tissues.